Literature DB >> 3785141

Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion.

P A Andrews, M P Murphy, S B Howell.   

Abstract

We have investigated the role of glutathione in determining the macromolecular binding and cytotoxicity of cisplatin (DDP) and melphalan (LPAM) in human ovarian carcinoma cells and DDP-resistant L1210 mouse leukemia cells. Glutathione reacted avidly with DDP in normal saline with a bimolecular rate constant of 16.2 M-1 hr-1. Glutathione had no effect on the rate of hydrolysis of LPAM, consistent with the SN1-like reaction mechanism of LPAM. Glutathione protected calf thymus DNA and bovine serum albumin from DDP platination and LPAM alkylation. Glutathione also protected nuclei isolated from human ovarian carcinoma cells from DDP platination. The importance of intracellular glutathione in determining the cytotoxicity of DDP and LPAM was assessed by depletion of glutathione with buthionine sulfoximine in three cell types. Exposure to 0.5 mM buthionine sulfoximine for 20-28 hr depleted glutathione to levels that were 10-20% of control levels. COLO 316 and 2008 human ovarian carcinoma cells, and ZCR9 mouse leukemia cells were all sensitized to LPAM cytotoxicity by this level of glutathione depletion. The dose modification factors, defined as the IC50 control cells/IC50 depleted cells, were: 2.6 +/- 0.5 for COLO 316 cells, 1.6 +/- 0.1 for 2008 cells, and 2.1 +/- 1.1 for ZCR9 cells. In contrast, glutathione depletion had a minimal effect on DDP cytotoxicity in these cells with dose modification factors of: 1.2 +/- 0.2 for COLO 316 cells, 0.8 +/- 0.3 for 2008 cells, and 1.1 +/- 0.1 for ZCR9 cells. The differential potentiation of DDP and LPAM cytotoxicity by glutathione depletion in these cells, despite the similar protection that glutathione affords macromolecules from drug binding, suggests that there are fundamental differences in the intracellular interaction of these electrophilic drugs with glutathione.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3785141

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum.

Authors:  K Ikeda; K Miura; S Himeno; N Imura; A Naganuma
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.

Authors:  K J Scanlon; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

Review 3.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Systemic chemotherapy for malignant melanoma.

Authors:  A S Coates
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

5.  Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line.

Authors:  E Kimura; R E Enns; F Thiebaut; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Trans labilization of am(m)ine ligands from platinum(II) complexes by cancer cell extracts.

Authors:  Yonit Kasherman; Stefan Sturup; Dan Gibson
Journal:  J Biol Inorg Chem       Date:  2008-12-04       Impact factor: 3.358

Review 7.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

8.  The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.

Authors:  J E Melvik; J M Dornish; E O Pettersen
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.